24 September 2018 - PHARMAC is pleased to announce the approval of an agreement with Novartis for the supply of epoetin alfa.

The effect of the decision is that:

• The funded brand of epoetin alfa will change from Eprex, supplied by Janssen, to Binocrit, supplied by Novartis.
  
• Binocrit will be listed from 1 February 2019 and will become the only funded brand of epoetin alfa after a 5-month transition period.
  

Read PHARMAC notification